Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T21:58:39.135Z.
Calculation as of: 2026-10-06T21:58:39.135Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b864e21534e19d3622fdd1df0bfa06a86802ee3b4002ae0b13a65066f94ec11b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Viridian Therapeutics, Inc.
Market Cap
$2.06B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.06B
Operating Cash Flow Yield
N/A
TTM Avg
13.24%
3Y Avg
20.26%
5Y Avg
21.41%
Market Cap
$2.05B
Operating Cash Flow Yield
3.40%
TTM Avg
3.04%
3Y Avg
2.35%
5Y Avg
2.06%
Market Cap
$2.03B
Operating Cash Flow Yield
12.18%
TTM Avg
10.56%
3Y Avg
8.92%
5Y Avg
5.93%
Market Cap
$2.02B
Operating Cash Flow Yield
17.81%
TTM Avg
10.04%
3Y Avg
8.73%
5Y Avg
8.73%
Market Cap
$2.11B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.02B
Operating Cash Flow Yield
N/A
TTM Avg
2.02%
3Y Avg
2.02%
5Y Avg
2.02%
Market Cap
$2.02B
Operating Cash Flow Yield
8.61%
TTM Avg
6.71%
3Y Avg
5.45%
5Y Avg
5.45%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viridian Therapeutics, Inc. (VRDN) | $2.06B | N/A | N/A | N/A | N/A |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | N/A | 13.24% | 20.26% | 21.41% |
| Alvotech (ALVO)vs › | $2.08B | N/A | N/A | N/A | N/A |
| Vericel Corporation (VCEL)vs › | $2.05B | 3.40% | 3.04% | 2.35% | 2.06% |
| Progyny, Inc. (PGNY)vs › | $2.03B | 12.18% | 10.56% | 8.92% | 5.93% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | 17.81% | 10.04% | 8.73% | 8.73% |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | N/A | N/A | N/A | N/A |
| UroGen Pharma Ltd. (URGN)vs › | $2.02B | N/A | 2.02% | 2.02% | 2.02% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 8.61% | 6.71% | 5.45% | 5.45% |
| Vera Therapeutics, Inc. (VERA)vs › | $2.11B | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
